Apellis Pharmaceuticals Cost Of Revenue Over Time
| APLS Stock | USD 33.90 0.12 0.35% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Apellis Pharmaceuticals Performance and Apellis Pharmaceuticals Correlation. Apellis |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Apellis Pharmaceuticals. If investors know Apellis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Apellis Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.03) | Revenue Per Share 5.811 | Quarterly Revenue Growth 0.783 | Return On Assets (0.16) | Return On Equity (1.07) |
The market value of Apellis Pharmaceuticals is measured differently than its book value, which is the value of Apellis that is recorded on the company's balance sheet. Investors also form their own opinion of Apellis Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Apellis Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Apellis Pharmaceuticals' market value can be influenced by many factors that don't directly affect Apellis Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Apellis Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Apellis Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Apellis Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Cost Of Revenue Analysis
Compare Apellis Pharmaceuticals and related stocks such as Prometheus Biosciences, Akero Therapeutics, and Immunovant Cost Of Revenue Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AKRO | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 80.2 M | 80.2 M | 100.9 M | 260 K | 29 K | 27.6 K |
| IMVT | 21 K | 21 K | 21 K | 21 K | 21 K | 21 K | 21 K | 21 K | 21 K | 21 K | 998 K | 1.2 M | 1.3 M | 231 K | 219.4 K |
| MDGL | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 156 | 77 K | 96 K | 112 K | 471 K | 405 K | 467 K | 527 K | 553.4 K |
| DAWN | 155 K | 155 K | 155 K | 155 K | 155 K | 155 K | 155 K | 155 K | 155 K | 155 K | 155 K | 199 K | 531 K | 383 K | 348.7 K |
| TERN | 65 K | 65 K | 65 K | 65 K | 65 K | 65 K | 65 K | 65 K | 65 K | 195 K | 394 K | 512 K | 1 M | 881 K | 564.5 K |
| XFOR | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 672 K | 1.9 M | 1.9 M | 2 M | 2 M | 1 M |
| INZY | 83 K | 83 K | 83 K | 83 K | 83 K | 83 K | 83 K | 83 K | 83 K | 83 K | 217 K | 1.1 M | 1.2 M | 1.3 M | 841.1 K |
| MREO | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 24.6 M | 34.6 M | 22.7 M | 23.6 M | 16.3 M | 17.9 M | 936 K | 2.6 M | 2.4 M |
| BPMC | 15.9 M | 15.9 M | 15.9 M | 15.9 M | 31.8 M | 48.6 M | 81.1 M | 144.7 M | 243.6 M | 331.4 M | 425 K | 17.9 M | 17.8 M | 12.8 M | 12.2 M |
| ABOS | 8.6 K | 8.6 K | 8.6 K | 8.6 K | 8.6 K | 8.6 K | 8.6 K | 8.6 K | 8.6 K | 8.6 K | 8 K | 4 K | 169 K | 42.3 M | 44.4 M |
Apellis Pharmaceuticals and related stocks such as Prometheus Biosciences, Akero Therapeutics, and Immunovant Cost Of Revenue description
Cost of Revenue is found on Apellis Pharmaceuticals income statement and represents the costs associated with goods and services Apellis Pharmaceuticals provides. Indirect cost, such as salaries, is not included. In other words, cost of revenue is the total cost incurred to obtain a sale. It is more than the traditional cost of goods sold, since it includes specific selling and marketing activities.My Equities
My Current Equities and Potential Positions
| Apellis Pharmaceuticals | APLS |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | Massachusetts; U.S.A |
| Exchange | NASDAQ Exchange |
USD 33.9
Additional Tools for Apellis Stock Analysis
When running Apellis Pharmaceuticals' price analysis, check to measure Apellis Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Apellis Pharmaceuticals is operating at the current time. Most of Apellis Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Apellis Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Apellis Pharmaceuticals' price. Additionally, you may evaluate how the addition of Apellis Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.